Latest Conference Articles

The protocol of pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy for muscle-invasive bladder cancer demonstrated safety and efficacy.

The FOLFOXIRI regimen in combination with bevacizumab is preferred over FOLFOXIRI plus cetuximab for the treatment of patients with RAS wild type, BRAF V600E mutant metastatic colorectal cancer.

In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.

Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with the combination of ibrutinib plus venetoclax had complete response and complete response with a 56% incomplete bone marrow recover rate in the phase 2 CAPTIVATe study.

Benefit was maintained in progression-free survival, overall survival, and objective response rate with the antibody-drug conjugate sacituzumab govitecan over physician’s choice of therapy, regardless of the chemotherapy agent used.

Similar health-reatled quality of life outcomes and disease-related symptom scores were seen between the combination of lenvatinib plus pembrolizumab and sunitinib for the frontline treatment of metastatic renal cell carcinoma.

In select previously treated patients with chronic lymphocytic leukemia, treatment with acalabrutinib was found to be noninferior but better tolerated compared with ibrutinib.

Across 3 HER2-negative biomarker signature groups, treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel increased estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer, but the results were not considered significant, according to findings from the phase 2 I-SPY 2 trial.

Promising responses and disease control rates were observed with larotrectinib administered as treatment of patients with TRK fusion-positive central nervous system tumors.

Investigators in the PALOMA-3 trial have concluded that Palbociclib plus fulvestrant maintains a clinically meaningful long-term overall survival benefit for patients with either HR+ or HER2 negative breast cancer.

Data from the phase 2 NIFTY trial demonstrated that a combination with liposomal irinotecan significantly improved survival in patients with metastatic biliary tract cancer.

Looking at 6.5 years of follow-up data from the phase 3 CheckMate-067 trial shows maintained outcomes in patients with advanced melanoma on nivolumab alone, or with ipilimumab.

Further follow up of lifileucel in patients with melanoma showed potentially follow progression on anti—PD-1 therapy.

Pediatric patients with advanced RET-altered solid tumors showed preliminary efficacy with selpercatinib, according to data presented at the 2021 ASCO Annual Meeting.

Updated findings show how selpercatinib improves responses in patients with RET-mutant medullary thyroid cancer regardless of the prior treatment they had.

Patients with early-stage breast cancer who have ultralow risk disease, indicated by a 70-gene signature, demonstrated an excellent survival prognosis regardless of clinical risk.

New data from the phase 3 IMPACT trial shows the advantages and shortcomings of gefitinib in patients with EGFR-mutant non-small cell lung cancer.

Results from phase 1 data looking at CART-ddBCMA show a 100% objective response rate among patients with relapsed/refractory multiple myeloma.

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma, efficacy results continue to show a durable response.

Results from a phase 2 trial of patients with HER2-positive breast comparing TCbH alone and TCbH with pyrotinib showed significant improvement when adding pyrotinib, according to data presented at ASCO.

Utilizing a de-escalation of treatment strategy, researchers found a high response and significant results among patients with HER2+ breast cancer.

Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.

Treatment-naïve patients with melanoma who crossed over to receive pembrolizumab had an ORR of 38.8% and a 3-year PFS of 32% according to updated data from the phase 3 EORTX 1325/KEYNOTE-054 trial.

The combination of tafasitamab-cxix and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma showed sustainable responses at 3-year follow-up of the phase 2 L-MIND trial.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Overall survival was maintained, and even improved, in patients with pretreated HER2-positive breast cancer receiving tucatinib plus trastuzumab and capecitabine versus placebo.

No clinical activity was elicited by selumetinib in pediatric and young adult patients with refractory cancers.

In patients with advanced or metastatic esophageal squamous cell carcinoma, Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy.

Overall survival in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up continued to improve with Ribociclib plus fulvestrant over fulvestrant alone, irrespective of whether patients received the regimen in the first- or second-line setting.

Encouraging clinical and pharmacodynamic activity was seen at all dose levels in patients with B-cell malignancies who received TG-1701.